Risk Score, if Premenopausal, Serum
Use
The Risk Score for premenopausal women is used to calculate the risk assessment for finding an ovarian malignancy during surgery in women who present with an adnexal mass. This calculation incorporates cancer antigen 125 (CA125), human epididymal protein 4 (HE4), and menopausal status to classify women into high-risk or low-risk groups for finding an ovarian malignancy. This assessment is crucial for determining the appropriate course of surgical intervention.
Special Instructions
Not provided.
Limitations
The Risk Score should be interpreted in conjunction with clinical and radiological assessment. It is indicated for women older than 18 who present with an adnexal mass planned for surgery and who have not yet been referred to an oncologist. The algorithm provides a guideline but should be considered alongside other diagnostic methods.
New York Approved
Methodology
Other
Biomarkers
Cancer Antigen 125 (CA125)
AnalyteHuman Epididymal Protein 4 (HE4)
AnalyteMenopausal Status
Other
LOINC Codes
- 69569-2 - ROMA score premen SerPl
- 69569-2 - ROMA score premen SerPl
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 48 hours |
| Frozen | 84 days |